Australia's most trusted
source of pharma news
Posted 23 September 2021 AM
Rare disease patient groups have voted Roche as "best" pharma for overall corporate reputation and "best" in its response to tackling COVID-19, according to a newly released PatientView survey.
Takeda came in second place followed by Pfizer in third, after an assessment of 29 companies with which patient groups were familiar, according to the Corporate Reputation of Pharma 2020, Perspective of Rare Disease Patient Groups Report.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.